Clare E. Collins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Clare E. Collins has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
C Mews
Department of Gastroenterology, Princess Margaret Hospital for Children, Perth, WA
1 shared publicationD Stapleton
Department of Nutrition and Dietetics, Princess Margaret Hospital for Children, Perth, WA, Australia
1 shared publicationEdward V O’loughlin
1 shared publicationEdward V. O'LOughlin
Department of Gastroenterology The New Children's Hospital Westnmead Sydney New South Wales 2145 Australia
1 shared publicationG Davidson
Gastroenterology Unit, Women’s and Children’s Hospital, North Adelaide, SA
1 shared publicationH Anthony
Department of Nutrition, Royal Children's Hospital, Parkville, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 1 September 1999
- Published by BMJ in Archives of Disease in Childhood
- Vol. 81 (3) , 241-246
Normal growth in cystic fibrosis associated with a specialised centre
OBJECTIVE To assess the impact of lifetime continuous care within the John Hunter Hospital cystic fibrosis (CF) clinics on growth and lung function. DESIGN A cross sectional survey of variables affecting nutritional status in CF was undertaken for 1993 and 1997. Data were retrieved from medical records and grouped into 5 year age bands. MAIN OUTCOME MEASURES Change in height z-score, weight centile, and forced expiratory volume in one second (FEV1) between patient cohorts receiving specialised care for different lengths of time. RESULTS Improved mean height z-score (−0.880 v −0.047) and weight centile (28.3% v 48.1%) for the 10–15 year age group in 1997, who had received continuous lifetime care within the clinic, compared with the same age group in 1993, for whom continuous medical care started at an older age. There was no corresponding improvement in FEV1, as an indicator of lung function, in this group (81.6% predicted v89.5% predicted). CONCLUSIONS This study suggests that lifetime continuous care within a specialised CF centre is associated with improved growth but not improved lung function.
- 1 September 1999
- Published by BMJ in Archives of Disease in Childhood
- Vol. 81 (3) , 241-246
Open AccessNormal growth in cystic fibrosis associated with a specialised centre
OBJECTIVE To assess the impact of lifetime continuous care within the John Hunter Hospital cystic fibrosis (CF) clinics on growth and lung function. DESIGN A cross sectional survey of variables affecting nutritional status in CF was undertaken for 1993 and 1997. Data were retrieved from medical records and grouped into 5 year age bands. MAIN OUTCOME MEASURES Change in height z-score, weight centile, and forced expiratory volume in one second (FEV1) between patient cohorts receiving specialised care for different lengths of time. RESULTS Improved mean height z-score (−0.880 v −0.047) and weight centile (28.3% v 48.1%) for the 10–15 year age group in 1997, who had received continuous lifetime care within the clinic, compared with the same age group in 1993, for whom continuous medical care started at an older age. There was no corresponding improvement in FEV1, as an indicator of lung function, in this group (81.6% predicted v89.5% predicted). CONCLUSIONS This study suggests that lifetime continuous care within a specialised CF centre is associated with improved growth but not improved lung function.
Elevated plasma levels of F2α isoprostane in cystic fibrosis
Cystic fibrosis (CT) is associated with chronic lung infection’ inflammation’ and elevated indices of oxidative stress. Recently’ isoprostanes were shown to be a reliable in vivo marker of oxidant injury with 8‐iso‐PGF2α’ shown to cause airflow obstruction and plasma exudation in guinea pig lung. The present study was designed to examine the relationship between 8‐iso‐PGF2α levels’ plasma antioxidants’ and clinical status in CF. We hypothesized that plasma 8‐iso‐PGF2α levels would be higher in subjects with CT compared to healthy controls. Plasma 8‐iso‐PGF2α levels were prospectively measured in 22 subjects with CF and nine healthy controls using an 8‐isoprostane enzyme immunoassay kit along with plasma vitamins A’ E’ and β‐carotene. Plasma 8‐iso‐PGF2α levels were shown to be significantly elevated in the CE subjects compared to controls (319.6±52.6 vs. 145.0±21.0 pg/ml’ P=0.005). Plasma levels of antioxidants were significantly lower for the CF subjects compared to the controls (vitamin A’PPPiso‐PGF2α levels.
Elevated plasma levels of F2α isoprostane in cystic fibrosis
Cystic fibrosis (CT) is associated with chronic lung infection’ inflammation’ and elevated indices of oxidative stress. Recently’ isoprostanes were shown to be a reliable in vivo marker of oxidant injury with 8‐iso‐PGF2α’ shown to cause airflow obstruction and plasma exudation in guinea pig lung. The present study was designed to examine the relationship between 8‐iso‐PGF2α levels’ plasma antioxidants’ and clinical status in CF. We hypothesized that plasma 8‐iso‐PGF2α levels would be higher in subjects with CT compared to healthy controls. Plasma 8‐iso‐PGF2α levels were prospectively measured in 22 subjects with CF and nine healthy controls using an 8‐isoprostane enzyme immunoassay kit along with plasma vitamins A’ E’ and β‐carotene. Plasma 8‐iso‐PGF2α levels were shown to be significantly elevated in the CE subjects compared to controls (319.6±52.6 vs. 145.0±21.0 pg/ml’ P=0.005). Plasma levels of antioxidants were significantly lower for the CF subjects compared to the controls (vitamin A’PPPiso‐PGF2α levels.
- 20 April 1999
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 35 (2) , 125-129
Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines
Pancreatic enzyme replacement therapy (PERT) is a major factor associated with achieving optimum growth and nutritional status in cystic fibrosis (CF) patients with pancreatic insufficiency and consequent malabsorption. Currently in Australian CF clinics policies for the usage of PERT vary considerably. This paper highlights the current issues related to fat absorption and use of PERT in CF. It also provides evidence to support the recommendation of a PERT dose based on a standard ratio of lipase units per gram of dietary fat consumed for individual patients. A consistent approach to PERT doses will facilitate identification of patients whose PERT intake increases their risk of fibrosing colonopathy and for whom gastroenterological review is warranted. Recent reports indicate that PERT intake can be reduced with a secondary improvement in growth and nutrition status as a consequence of increased dietetic input. These Australian guidelines for the judicious use of PERT in CF should lead not only to a refinement in nutritional management of patients with CF but should also facilitate an improvement in compliance with therapy due to sophistication in patient education materials. The Australian guidelines for the use of PERT in CF if correctly applied, will also provide patients and their families with a better understanding of the relationship between PERT and nutritional status.
- 20 April 1999
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 35 (2) , 125-129
Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines
Pancreatic enzyme replacement therapy (PERT) is a major factor associated with achieving optimum growth and nutritional status in cystic fibrosis (CF) patients with pancreatic insufficiency and consequent malabsorption. Currently in Australian CF clinics policies for the usage of PERT vary considerably. This paper highlights the current issues related to fat absorption and use of PERT in CF. It also provides evidence to support the recommendation of a PERT dose based on a standard ratio of lipase units per gram of dietary fat consumed for individual patients. A consistent approach to PERT doses will facilitate identification of patients whose PERT intake increases their risk of fibrosing colonopathy and for whom gastroenterological review is warranted. Recent reports indicate that PERT intake can be reduced with a secondary improvement in growth and nutrition status as a consequence of increased dietetic input. These Australian guidelines for the judicious use of PERT in CF should lead not only to a refinement in nutritional management of patients with CF but should also facilitate an improvement in compliance with therapy due to sophistication in patient education materials. The Australian guidelines for the use of PERT in CF if correctly applied, will also provide patients and their families with a better understanding of the relationship between PERT and nutritional status.